Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Aug;97(4):693-8.
doi: 10.1046/j.1365-2567.1999.00845.x.

Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites

Affiliations

Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites

J Schuurman et al. Immunology. 1999 Aug.

Abstract

Unlike other immunoglobulin G (IgG) subclasses, IgG4 antibodies in plasma have been reported to be functionally monovalent. In this paper we show that the apparent monovalency of circulating IgG4 is caused by asymmetry of plasma IgG4. A large fraction of plasma IgG4 molecules have two different antigen-binding sites, resulting in bispecificity. Sera from patients with IgG4 antibodies to both house dust mite and grass pollen induced cross-linking of Sepharose-bound grass pollen antigen to radiolabelled house dust mite allergen Der p I. This bispecific binding activity was not observed in sera with IgG4 antibodies to either grass pollen or house dust mite exclusively. Depletion of IgG4 antibodies resulted in disappearance of the bispecific activity. By size exclusion chromatography we excluded the possibility that bispecific activity was caused by aggregation of IgG4 antibodies. These results indicate that circulating (polyclonal) IgG4 antibodies have two different antigen-binding sites and therefore are functionally monovalent antibodies.

PubMed Disclaimer

Figures

Figure 2
Figure 2
The functional valency of chimeric IgG4, plasma #178 and affinity-purified IgG4 from plasma #178. (a) Binding of 125I-labelled Der p II to serial dilutions of chimeric IgG4 (17 μg/ml, •), plasma #178 (▵) and affinity purified IgG4 from plasma #178 (○) to Sepharose-coupled Staphylococcal Protein A were tested and used to determine the amount of Der p II-specific IgG124 in the plasma. (b) The cross-linking of Sepharose-coupled mite-extract to 125I-labelled Der p II by chimeric IgG4 (•), plasma #178 (▵) or affinity-purified IgG4 from plasma #178 (○) was expressed as the amount of radioactivity bound relative to the amount of radioactivity added.
Figure 1
Figure 1
The relative contribution of IgG4 to the total IgG124 antibody activity with respect to the binding of 125I-labelled Der p of plasma #178 was deduced from the comparison between Sepharose-coupled anti-IgG4 (○) and Sepharose-coupled Staphylococcal Protein A (•); the results obtained with the chimeric IgG4 antibody, 17 μg/ml, are also shown (anti-IgG4, ▵, Protein A, ▴).
Figure 3
Figure 3
The bispecific binding is not caused by Der p I contamination of the grass pollen–Sepharose. Serial dilutions of rabbit polyclonal antiserum to Der p (○, □) and plasma #741B (•, ▪) were incubated with protein A–Sepharose (○, •) or with grass pollen–Sepharose (□, ▪). The binding was detected using radiolabelled Der p I. The results were expressed as the amount of radioactivity bound relative to the amount of radioactivity added.
Figure 4
Figure 4
Gel filtration of serum #741. Serum #741, 200 μl was fractionated on an ACA 34 column. The fractions were tested for total amounts of IgE (180 000 MW, broken line), Der p II-specific IgG (solid line) and for the binding in the heterologous binding assay (•). The void volume is indicated by ▾. The results are expressed as percentage of starting material.
Figure 5
Figure 5
Depletion of IgG4 antibodies from serum #741. Serum #741 was depleted for IgG4 (▴). As control, a sample was also depleted for IgE (□) and incubated with control Sepharose (○). The three samples were tested for the amount of Der p I-specific IgG (a) and for the binding activity in the heterologous binding assay (b).

References

    1. Aalberse RC, Van Der Gaag R, Van Leeuwen J. Serological aspects of IgG4 antibodies I. Prolonged immunization results in an IgG4-restricted response. J Immunol. 1983;130:722. - PubMed
    1. Van Der Zee JS, Van Swieten P, Aalberse RC. Serological aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol. 1986;137:3566. - PubMed
    1. Brueggemann M, Williams GT, Bindon CI, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med. 1987;166:1351. - PMC - PubMed
    1. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol. 1993;23:1098. - PubMed
    1. Isaacs JD, Clark MR, Greenwood J, Waldmann H. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J Immunol. 1992;148:3062. - PubMed

Publication types

LinkOut - more resources